Fair Money & Economic Opportunity

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. The company generates revenue from the sale of pharmaceutical products and invests in research and development. The provided articles contain no evidence that the company offers lending, insurance, or any other financial services to consumers.

Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to the company's core business.

Fair Pay & Worker Respect

In 2023, Catalyst Pharmaceuticals reported a CEO to median employee pay ratio of 7:1.

The company achieved a 96% employee engagement score, with 90% of employees participating in the survey. There are no reported regulatory actions, violations, fines, or compliance issues related to labor laws or human rights in the provided articles.

Fair Trade & Ethical Sourcing

Catalyst Pharmaceuticals reported zero incidents of human rights violations, including child or forced labor, from itself or its suppliers in 2022, 2023, and 2024.

The company implements internal and third-party audit programs to monitor supplier practices. Catalyst utilizes the TraceLink system and GS1 standards to serialize all products for the U.S. market at the individual package level, tracking them through the distribution channel. Catalyst's Code of Business Conduct and Ethics and Policy on Human Rights and Dignity outline ethical principles and commit to preventing adverse human rights impacts, expecting business partners to adhere to the same standards and comply with national human rights law.

Kind to Animals

Catalyst Pharmaceuticals utilizes animal testing in its research and development, stating that it obtains safety data and proves compound efficacy.

The company does not have a publicly available policy to restrict or reduce animal testing. In 2008, a study involved 50 adolescent and adult animals genetically bred to be obese. As of 2024, around 50% of Tier 1 supplier facilities participate in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program. Catalyst is a member of Biotechnology Innovation Organization (BIO) and BioFlorida, which support advocacy and medical research, but there is no specific public position or active engagement on animal welfare legislation.

Planet-Friendly Business

In 2024, Catalyst Pharmaceuticals reported Scope 1 emissions of 3.6 tCO2e and Scope 2 emissions of 51.0 tCO2e, totaling 54.6 tCO2e.

A value chain assessment to identify relevant categories of Scope 3 emissions is underway. The company's single corporate office is located in a LEED Gold-certified green building. In 2023, the company generated 2.1 metric tons of waste and diverted 0.3 metric tons from disposal, while in 2024, it generated 2.1 metric tons and diverted 0.4 metric tons. The company's manufacturers reported no environmental violations or significant direct exposures in 2023 or 2024. Catalyst is undertaking preparedness activities to align with TCFD recommendations and took preliminary actions in 2024, identifying and assessing climate-related risks and opportunities. Climate-related risks and opportunities were stress-tested. The LEED-certified building's landscaping utilizes native and adaptive plants, reducing irrigation needs. Approximately 63% of Catalyst's Tier 1 supplier facilities participate in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program, and 63% of Tier 1 suppliers' facilities have achieved ISO 140001 or HAZWOPER certification.

Respect for Cultures & Communities

Catalyst Pharmaceuticals reported zero cultural appropriation incidents in 2022.

A cultural impact assessment protocol is mentioned as being in place, but no details on its implementation are provided. The local employment ratio in 2022 was 42.1% for commercial, 30.3% for R&D, and 27.6% for general/administrative roles. In 2023, the company made $5,900,000 in charitable donations to patient support, advocacy, and medication education organizations, but no specific percentage of revenue was directed to cultural heritage organizations. All employees completed Code of Conduct training in 2022, with additional training for Medical Affairs and Commercial employees, but specific cultural sensitivity training completion rates are not provided.

Safe & Smart Tech

Catalyst RCM experienced a data breach in November 2025, involving sensitive information such as names, dates of birth, payment card details, medical treatment details, medical histories, diagnosis information, and health insurance information.

Attorneys are investigating a class action lawsuit related to this incident. In contrast, Catalyst Pharmaceuticals reported zero cybersecurity incidents in 2024 and stated that no cybersecurity challenges materially impaired its operations or financial standing in 2024. The company conducts monthly cybersecurity training for employees, and 100% of employees completed Code of Business Conduct and Ethics training in 2024. Medical Affairs and Commercial employees receive initial and routine follow-up training. Catalyst identifies cyber breaches and data security concerns as risks in its annual risk assessment and has a well-defined incident response plan. The company has a Responsible Disclosure Policy for vulnerability reporting but does not offer rewards through this program. It leverages a third party for penetration testing. Catalyst collects various categories of personal information, including health insurance and medical information, and records service calls to and from Catalyst Pathways. It retains data for purposes such as meeting regulatory obligations and business planning. The company states it does not sell personal information to third parties. Catalyst adheres to HIPAA, HITECH, and CCPA, and its manufacturing facilities are subject to FDA inspections.